Janssen Highlights its Hepatitis C Clinical Development Program in Advance of...
Janssen Logo. Facebook Twitter Pinterest × Janssen Logo. BOSTON, Nov. 7, 2014 /PRNewswire/ -- Janssen R&D Ireland (Janssen) highlights its hepatitis C (HCV) clinical development program in advance...
View ArticleJanssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral,...
(Source: Johnson & Johnson) July 23, 2015 Janssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral, Once-Daily OLYSIO® (Simeprevir) in Combination with Sofosbuvir Filing Supported...
View ArticleJanssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral,...
TITUSVILLE, N.J., July 23, 2015 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced the submission of a supplemental New Drug Application (sNDA) to the...
View ArticleJanssen Announces Collaboration with Gilead to Develop PREZISTA®-based...
-- Two Companies to also Collaborate on the Further Development of Complera®, Marketed as Eviplera® in the European Union -- CORK, Ireland, Dec. 29, 2014 /CNW/ - Janssen R&D Ireland (Janssen)...
View ArticleJanssen Announces Collaboration with Gilead to Develop PREZISTA®-based...
Janssen Logo. (PRNewsFoto/Janssen Pharmaceutical Companies) Facebook Twitter Pinterest × Janssen Logo. (PRNewsFoto/Janssen Pharmaceutical Companies) CORK, Ireland, December 29, 2014 /PRNewswire/ -- --...
View ArticlePREZCOBIX™ (darunavir/cobicistat) Approved in the U.S. for the Treatment of...
PREZCOBIX(TM) (darunavir 800mg / cobicistat 150mg) Tablets Facebook Twitter Pinterest PREZCOBIX(TM) (darunavir 800mg / cobicistat 150mg) Bottle Facebook Twitter Pinterest PREZCOBIX(TM) Logo Facebook...
View ArticleYour Story, Your HIV Wisdom™ Brings Together HIV Voices and Supports HIV...
(Source: Johnson & Johnson) Notable HIV Advocates Highlight Perspectives of People Living with or Affected by HIV to Leverage Shared Support and Self-Expression TITUSVILLE, N.J., September 8, 2015...
View ArticleYour Story, Your HIV Wisdom™ Brings Together HIV Voices and Supports HIV...
TITUSVILLE, N.J., Sept. 8, 2015 /PRNewswire/ -- Seeking and sharing information are important parts of the HIV journey – in fact, 80 percent of people living with HIV said they give advice or tell...
View ArticlePREZCOBIX™ (darunavir/cobicistat) Approved in the U.S. for the Treatment of...
(Source: Johnson & Johnson) Combined Fixed-Dose Tablet of Darunavir and Cobicistat Can Help Reduce Number of Pills in a Combination Antiretroviral Treatment Regimen TITUSVILLE, NJ, January 29, 2015...
View ArticleU.S. FDA Approves PREZISTA® (darunavir) for Use in Pregnant Women with HIV...
(Source: Johnson & Johnson) Data shows PREZISTA is a safe and effective treatment option in pregnant women, with no reports of mother-to-child HIV transmission among women who continued therapy...
View ArticleTECHNIVIE™ (ombitasvir, paritaprevir, and ritonavir tablets) Receives FDA...
(Source: AbbVie Inc) - TECHNIVIE provides an opportunity to treat adults in the U.S. who have genotype 4 (GT4) chronic hepatitis C virus (HCV) infection without cirrhosis, a population historically...
View ArticleTECHNIVIE(TM) (ombitasvir, paritaprevir, and ritonavir tablets) Receives FDA...
- TECHNIVIE provides an opportunity to treat adults in the U.S. who have genotype 4 (GT4) chronic hepatitis C virus (HCV) infection without cirrhosis, a population historically considered...
View ArticleTECHNIVIE™ (ombitasvir, paritaprevir, and ritonavir tablets) Receives FDA...
NORTH CHICAGO, Ill., July 24, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global, research-based biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved...
View ArticleAbbVie's Commitment to Gastroenterology and Hepatology Showcased at Digestive...
(Source: AbbVie Inc) AbbVie's Commitment to Gastroenterology and Hepatology Showcased at Digestive Disease Week® (DDW) 2015 - May 12, 2015 IT STARTS WITH SCIENCE AND ENDS WITH A NEW WAY FORWARD -...
View ArticleAbbVie's Commitment to Gastroenterology and Hepatology Showcased at Digestive...
NORTH CHICAGO, Ill., May 12, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that 18 abstracts in its gastroenterology and hepatology programs will be presented at Digestive Disease Week® (DDW)...
View ArticleViiV starts PhIII LA injectable treatment regimen (GSK - GlaxoSmithKline plc)
(Source: GSK - GlaxoSmithKline plc) PRESS RELEASE ViiV Healthcare launches phase III programme to evaluate a long-acting, injectable HIV treatment regimen Studies will investigate monthly dosing with...
View ArticleViiV Healthcare announces phase II study results for first two drug,...
(Source: GSK - GlaxoSmithKline plc) 32 week maintenance data presented at CROI showed comparable viral suppression rates between injectable regimen and three drug oral regimen Issued: London London,...
View ArticleFirst Regimen Combining Long Acting Injectable Antiretrovirals; 32-Week LATTE...
(Source: Johnson & Johnson) Intramuscular 2-drug maintenance therapy demonstrates comparable antiviral activity to daily oral 3-drug combination CORK, Ireland, - February 24, 2016 - Janssen...
View ArticleViiV Healthcare begins phase III programme with dolutegravir/rilpivirine...
(Source: GSK - GlaxoSmithKline plc) 06 May 2015 First programme to evaluate dual HIV maintenance therapy with dolutegravir and rilpivirine London, United Kingdom, 6 May 2015: ViiV Healthcare today...
View ArticleViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine...
First programme to evaluate dual HIV maintenance therapy with dolutegravir and rilpivirine LONDON, May 6, 2015 /CNW/ - ViiV Healthcare today announced the start of a Phase III clinical trial programme...
View Article